There are 3484 resources available
Current standard of care in adjuvant / neoadjuvant therapy of operable NSCLC
Presenter: Heather Wakelee
Session: Adjuvant / neoadjuvant therapy of operable NSCLC in 2023
Resources:
Slides
Webcast
Induction versus adjuvant chemotherapy in LA-NPC: Deciphering the latest evidence for the practicing oncologist
Presenter: Pierre Blanchard
Session: Advances in the management of locally advanced NPC
Resources:
Slides
Webcast
656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study
Presenter: Yiming Zhao
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
657MO - Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
Presenter: Bob Li
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1693MO - The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study
Presenter: Silvie Janssen
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Presenter: Aaron Lisberg
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
Predictive biomarkers for adjuvant / neoadjuvant IO
Presenter: Nicolas Girard
Session: Adjuvant / neoadjuvant therapy of operable NSCLC in 2023
Resources:
Webcast
Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC
Presenter: Melvin Lee Kiang Chua
Session: Advances in the management of locally advanced NPC
Resources:
Slides
Webcast
LBA34 - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Presenter: Funda Meric-Bernstam
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1694MO - Socio-economic consequences among adolescent and young adult cancer patients: A European perspective
Presenter: Silvie Janssen
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast